Related Experiment Videos
Projected life-expectancy gains with statin therapy for individuals with elevated C-reactive protein levels
Gavin J Blake1, Paul M Ridker, Karen M Kuntz
1Center for Cardiovascular Disease Prevention, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Insights
Statin therapy may significantly increase life expectancy for individuals with elevated C-reactive protein (CRP) levels, even without high cholesterol. This finding suggests broader eligibility for statins in cardiovascular disease prevention.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Preventive Cardiology
Background:
- Elevated C-reactive protein (CRP) indicates increased cardiovascular disease (CVD) risk.
- Individuals with low LDL cholesterol below treatment guidelines but high CRP may benefit from statins.
Purpose of the Study:
- To estimate life expectancy gains from statin therapy in individuals with elevated CRP but not overt hyperlipidemia.
- To assess the potential benefit of statins in a population not currently meeting treatment guidelines.
Main Methods:
- A decision-analytic model was developed to simulate life expectancy outcomes.
- Data from randomized trials informed statin efficacy and risks of myocardial infarction (MI) and stroke.
- Population-based studies provided post-MI/stroke prognosis estimates.
Main Results:
- Estimated life expectancy gains of approximately 6.4-6.7 months for 58-year-old men and women with elevated CRP (≥0.16 mg/dl) and LDL cholesterol <149 mg/dl.
- Gains were comparable to those in patients with LDL cholesterol ≥149 mg/dl.
- Baseline CVD risk and statin's MI prevention efficacy were key determinants of benefit magnitude.
Conclusions:
- Elevated CRP levels, even without hyperlipidemia, may indicate substantial benefit from statin therapy.
- Current treatment guidelines may under-identify individuals who could benefit from statins.
- Further intervention trials targeting individuals with elevated CRP are warranted.
Objectives:
We sought to estimate the potential gains in life expectancy achieved with statin therapy for individuals without overt hyperlipidemia but with elevated C-reactive protein (CRP) levels.
Background:
Persons with low-density lipoprotein (LDL) cholesterol levels below current treatment guidelines and elevated CRP levels are at increased risk of cardiovascular disease and may benefit from statin therapy.
Methods:
We constructed a decision-analytic model to estimate the gains in life expectancy with statin therapy for individuals without overt hyperlipidemia but with elevated CRP levels. The annual risks of myocardial infarction (MI) and stroke, as well as the efficacy of statin therapy, were based on evidence from randomized trials. Estimates of prognosis after MI or stroke were derived from population-based studies.
Results:
We estimated that 58-year-old men and women with CRP levels >or=0.16 mg/dl but LDL cholesterol <149 mg/dl would gain 6.6 months and 6.4 months of life expectancy, respectively, with statin therapy. These gains were similar to those for patients with LDL cholesterol >or=149 mg/dl (6.7 months for men and 6.6 months for women). In sensitivity analyses, we identified the baseline risk of MI and the efficacy of statin therapy for preventing MI as the most important factors in determining the magnitude of benefit with statin therapy.
Conclusions:
Our results suggest that individuals with elevated CRP levels, many of whom do not meet current National Cholesterol Education Program guidelines for drug treatment, may receive a substantial benefit from statin therapy. This analysis supports a crucial need for direct intervention trials aimed at subjects with elevated CRP levels.